Good day, everyone. This is Glenn Schulman, Head of Investor Relations, and I'd like to thank you all for joining us today as we report Galapagos's full year 2025 financial results and fourth quarter business update.

Last evening, we issued a press release outlining these results. This release, along with today's presentation, can be found on the Galapagos investor website at www.glpg.com.

Before we begin, I would like to remind everyone that we will be making forward-looking statements. These forward-looking statements include remarks concerning future developments of our company and our pipeline and possible changes in the industry and competitive environment.

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those indicated by these statements and are accurate only as of the date of this recording, February 24th, 2026.

Galapagos is not under any obligation to update statements regarding the future or to conform to these statements in relation to actual results, unless required by law. You are cautioned not to place any undue reliance on these statements.

Joining us on today's call from the executive team are Henry Gosebruch, Chief Executive Officer; Aaron Cox, Chief Financial Officer; Seowon Kwan, Chief Business Officer; and Dan Grossman, Chief Strategy Officer of the company, all of whom will be available during the Q&A session. With all that, let me now turn the call over to Henry Gosebruch, CEO of Galapagos.

Henry?

Thank you, Glenn, and thank you all for joining us today. Galapagos had a transformative 2025, focused on turning the page from cell therapy, implementing a new strategic direction, and laying a strong foundation for long-term value creation.

We are entering this new chapter with approximately €3 billion in cash at year-end 2025 and a strong position to pursue transformative business development opportunities with significant strategic flexibility. The new team is in place to execute on the strategic vision.

We have been very deliberate in assembling the right leadership team to execute the strategy, and I could not be more pleased with the level of talent we've been able to attract to Galapagos. We've assembled a management team with world-class business development expertise and a shared mission of leveraging our unique position to create significant shareholder value.

Collectively, our team has executed hundreds of transactions in the life sciences sector and is working well together with the goal of creating value for our shareholders. We have also evolved our board composition, welcoming five new directors who bring the deep transaction, capital allocation, and operating experiences needed for this next phase of growth.

Our objective is not incremental rebuilding, but a fundamental reshaping of the company around programs we believe are capable of delivering meaningful patient impact and sustainable shareholder returns. We are aggressively evaluating opportunities across our focus areas and maintaining a broad dialogue with companies and innovators globally.

We are encouraged by the level of potential transactions we have in our deal pipeline and our opportunity to become a unique player in the biotech deal ecosystem and carve out niches where we can be competitively differentiated. At the same time, we are disciplined and selective.

We will allocate our capital carefully and thoughtfully, with clear financial metrics in mind. Our focus remains on clinically de-risked opportunities in areas where we are able to bring unique insights that represent competitive advantage.

Lastly, our collaboration with Gilead remains a key strategic advantage and potential competitive differentiation. We are working very closely with Gilead and continue to have active and constructive dialogue as we evaluate opportunities.

Their global development and commercialization expertise, combined with our capital base, agility, and deal-making skills, creates a powerful platform as we shape this next phase of growth for Galapagos. Let me briefly provide an update on our legacy R&D asset, TYK2 or GLPG3667.

In December, we announced topline Phase 2 results for GLPG3667 in patients with dermatomyositis and systemic lupus erythematosus, or SLE. GLPG3667 met the primary endpoint in the dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo.

We are currently evaluating all strategic options for this program, including pursuing potential partnerships with other I&I players to accelerate the development of GLPG3667. In conclusion, Galapagos is well-positioned for the future.

Our year-end cash position of approximately €3 billion, our strong business development and capital allocation experience provide the strategic flexibility to pursue business development opportunities while maintaining a disciplined focus on value creation. With that overview, I would like to now turn the call over to Aaron Cox, our CFO, to review our full year 2025 financial results and 2026 guidance.

Aaron?

Thanks, Henry, and hello, everyone. In the press release issued last night, we detailed our full year 2025 results, provided an update on fourth quarter performance, and shared our 2026 guidance.

Total operating profit from continuing operations amounted to €295.1 million in 2025, compared to an operating loss of €188.3 million in 2024. This operating profit was primarily due to the release in revenue of the remaining deferred income balance of €1,069 million associated with the exclusive access rights granted to Gilead under the OLCA.

As a reminder, in conjunction with this transaction in 2019, Galapagos recognized a contract liability of approximately €2.3 billion, which was to be recognized as revenue on a straight-line basis over the 10-year term of the agreement. Following the 2025 OLCA amendments, the intention to wind down, and related events in 2025, as of December 31st, it was assessed that there were no remaining obligations that would justify this specific contract liability to be maintained in our IFRS financial statements.

We do not expect any cash tax impact in 2025 related to this recognition of revenue. Importantly, while the OLCA still remains in force, we expect that any future business development transaction will be completed under terms that would be different than the existing terms of the OLCA.

Now turning to expenses. Operating expenses were negatively impacted for a total of €399.8 million by the decision to wind down the cell therapy activities, with an impact of €275 million consisting of an impairment of the cell therapy activities of €228.1 million, severance costs of €33.3 million, costs for early termination of collaborations of €16.3 million, deal costs of €10.1 million, €1.5 million for additional accelerated non-cash costs recognition for subscription right plans, and €7.5 million of other cost, partly offset by a positive fair value adjustment of the contingent consideration payable of €21.8 million.

Additionally, the executed strategic reorganization related to the small molecules business announced in 2025 for €124.8 million. Financial investments and cash and cash equivalents totaled €2,998 million on December 31st, 2025, as compared to €3,317.8 million on December 31st, 2024.

Our cash and cash equivalents and current financial investments included $2,159 million held in US dollars, versus $726.9 million on December 31st, 2024. These US dollars were translated to euros at an exchange rate of 1.175.

Since year-end, we have converted more euros to US dollars and now hold approximately 72% of our cash in US dollars and 28% in euros. We expect to continue increasing the portion of cash in US dollars as the year progresses.

Turning now to our guidance for 2026. As part of the transformation to the new Galapagos, we announced our intention to wind down our cell therapy activities last fall, and we are now executing on this process following the works councils processes that were completed last month.

Given the progress we've made on this execution, I can now share that we expect the cell therapy wind-down to be substantially completed by the end of the third quarter of 2026. In connection with the wind-down of the cell therapy activities, we expect an operating cash outflow of up to €50 million in Q1 2026, as well as one-time restructuring cash impact of €125 to €175 million in 2026.

This reflects a €25 million reduction compared to the prior guidance range of €150 million to €200 million. In addition, we anticipate cash costs of approximately €35 million to €40 million for the final implementation of the restructuring announced in January 2025.

Costs related to the ongoing TYK2 program, including completion of the Phase 2 clinical trials in DM and SLE, as well as ongoing support to advance the program toward Phase 3 development, are expected to be up to €40 million in 2026. Away from the spend items, we continue to expect meaningful cash flow to come from interest income, royalties, and tax credits.

As a result, we expect to be cash flow neutral to positive by the end of 2026. We also anticipate we will have approximately €2.775 billion to €2.85 billion in cash, cash equivalents, and financial investments at December 31st, 2026, excluding any business development activities or currency fluctuations.

Now let me turn it back to Henry to wrap up.

Thanks, Aaron. In closing, 2026 will be a pivotal year for Galapagos as we focus on building long-term value through transformative business development, leveraging our strong balance sheet, our deal-making expertise, and our unique collaboration with Gilead.

Our shares remain at a significant discount to the cash figures Aaron just reviewed. We will be focused on closing the gap through execution on our business development plan, thoughtful capital allocation, and engagement with shareholders to rebuild trust and confidence.

We are encouraged by the momentum we've built so far as we reshape Galapagos with a clear strategy in place. With a disciplined approach to capital allocation, we remain focused on pursuing the right opportunities to build a pipeline of novel therapeutics designed to deliver meaningful benefits for patients and a sustainable value for shareholders.

We are still early in this new chapter of our company, but we are off to a strong start and we are excited about the future ahead. With that, thank you all for your attention and we will now open it up for your questions.

Operator?

Hey, good morning. Thanks for taking my question.

Just as you continue to progress on business development, just kind of curious if anything has evolved in terms of what you might be looking for. Then, is there any deadline or any sort of change that we might expect based on the Gilead agreement if you're not able to identify assets to bring in by a certain time point?

Thanks.

Yeah. Hey, Brian.

It's Henry. I'll take those questions.

No, our strategy is really consistent with what we've been talking about since last fall in terms of focusing on de-risked, late-stage clinical assets, not exclusively, but primarily in the I&I and oncology space. I'd say we continue to see a lot of good opportunity there, and as we said in the prepared remarks, we're focusing on opportunities where we think we can bring unique insights, unique competitive advantage, but I think there's, again, a lot of opportunity and we're working through our deal funnel and remain confident that there's a lot of attractive opportunity for us.

With respect to your second question, as we've said previously, we're not going to set a deadline for a specific deal. Again, we'll remain patient, disciplined.

Again, we do have some good activity going on, but it's more important to do the right deal than to do a deal by a certain period of time. The OLCA does expire, now it doesn't expire for about three years and change, ultimately that is a deadline, but certainly we're focused on getting transformative transaction done ahead of that ultimate expiration of OLCA.

Got it. If something does not happen before then?

If something does not happen by then, despite working really hard on trying to make it happen, then OLCA would expire and we would go on without the OLCA in place.

Thanks.

Morning and thanks for taking our question. Our question's on GLPG3667.

In the past, you've suggested that the bar to moving that forward internally and investing in it further would be rather high. We're curious to get an update on your thoughts there.

I know you said you're pursuing all possible avenues of moving that forward, but how does management weigh developing that internally and investing in it versus out-licensing? Thanks.

Phil. I would say those comments also stand.

We have a high bar. Frankly, we have a high bar not just for 3667, but for any asset, be it internal or external.

We really look at it with the same unbiased lens. Now with respect to where we are, again, it's still early.

We, as got the topline data just before the holiday, data's still coming in, we don't have the full package in place. We are in the process of talking to partners, again, given that we don't have the full infrastructure required to really take this into Phase 3, it makes sense to see where some of the players are that have that and maybe in working with a partner, we can do more, do it faster, do it more capital efficient, and ultimately create more value.

We're focused on looking at that, we're focused on getting our arms around the data that's still trickling in, but, again, the bar's exactly the same bar that we've always set for ourselves.

That's very helpful. Thank you.

Hi guys, thanks for the question. Can you speak to your current view on capital allocation, specifically as it relates to the pool of capital you aim to put forth for acquisitions for BD and how much you need to reserve for operating expenses going forward and how the Gilead partnership informs deal sizing and optionality on that front?

Thanks.

It's Henry. Thanks for the question.

Look, at a high level, some of what I'm going to say is pretty obvious, but we have €3 billion in capital, and as you point out, that capital needs to account both for any consideration to a partner or acquisition target and, of course, our development expenses we would have in any transaction. Now, when you say, sort of, how does the relationship with Gilead inform our capital allocation?

As we said on calls previously, the dialogue with Gilead is quite strong, it's very, very constructive. They continue to indicate openness to contribute in both deal terms, meaning paying some of the upfront consideration, as well as taking on some of the development spend operation.

Ultimately, in working with Gilead, we can go beyond the €3 billion we have, and I think that's one of the features we think is very attractive in working with Gilead. As we think through it, we don't just think about our pool of capital, we also think about what in working with Gilead can we add to the pie, and therefore, go beyond what we could do on our own.

I don't know if that's where you were going with your question or if you want to clarify maybe what I didn't answer.

No, I think that covers it. Thanks.

Good. Thank you.

Thanks, Ma'am. I think in the Q&A queue, we do have one more or a couple more coming in, if possible would be great to take.

I think there's a question from KBC.

Hi, yeah, Mathijs coming in for Jacob. I had a question on the lower cell therapy wind-down costs.

Do you maybe expect that to lower further in the future or you don't see any possibility in that?

Mathijs, thanks, it's Henry, thanks for getting the question. I'll let Aaron answer that.

Thanks. We're not providing future guidance here, but we'll obviously update folks on how that cost envelope is progressing on future calls.

Yes, we did lower the range from a previous range of €150 to €200 million in terms of one-time restructuring cost. We lowered that range by €25 million with this release, and as we continue to progress through the wind-down, we'll provide updated costs on future calls.

Thanks. Thank you.

Hello, hi, good morning, everybody. I was wondering and coming back to the capital allocation and the decision you've been taking and especially regarding the cash and the cash allocation, the move from euro to dollar, considering the fact that you didn't gain as much as financial income as last year.

I was questioning about what was the rationale on the back of that, what was the exact timing for us to be clear, and shall we consider the breakup of, let's say, 2/3 US, 1/3 euro as being the picture for your next investment portfolio or for the picture we should have from your investment income in the near future?

Thanks, Delphine. Mid-last year, we started transitioning more euros to dollars, and that was primarily based on where we expected our BD activity to be driven and also where our cost base is starting to move towards, which is more US-based.

We provided a range on this call of €2.775 to €2.85 billion for the year, and as I mentioned before, we'll update that as we go through the year. In terms of continued transition to US dollars, as you heard from my remarks, we do expect to transition more to US dollars as the year progresses, but still keeping a portion in euros as we still have meaningful operating expenses in euro denomination over the year as we move through this wind-down.

We do see higher earnings rates in terms of what we're receiving on our US dollars. As you look at rates across the environment, you could estimate euros earning around 2% and US dollars earning around 4%.

While the exchange rate does move, we are seeing significant uptake in terms of the interest earned on the US dollars versus euros.

All right. Can I ask another one or do you have to go back in the queue?

Go ahead, Delphine, go ahead.

Thank you very much. I was wondering if you have or if you can communicate any expectation regarding the break-even in term of operating income.

You cut out a little bit. You're asking about what regarding operating income?

When do you expect a break-even for the operating income?

Break-even. We've indicated we expect to be cash flow neutral to positive by year-end.

Obviously, as we work through the wind-down and associated costs, those costs are going to be chunky kind of throughout the year. It's hard to predict exactly which quarter some of those costs are going to fall in, but we do expect to be cash flow neutral to positive by year-end.

Yeah. Got it.

Thank you.

Thanks, Ma'am, and thanks everyone for taking the time to join us this morning on the call. Just a couple of upcoming activities on the investor relations front.

The Galapagos team is going to be at the TD Cowen conference next week, up in Boston, attending the Jefferies By The Beach conference in a couple of weeks, Kempen conference coming up in April 15th, and the Bank of America conference in May. Those interested in meeting with the team, please feel free to reach out to your sales contact at those respective institutions to schedule a meeting.

Lastly, just want to mention that our annual report will be filed near the end of March, March 26th, there'll be additional information coming out then, and if you need anything in the meantime, don't hesitate to reach out to me. Thank you all for your attention today, and have a great week.